Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria clinical trials

Explore recruiting polymyositis or dermatomyositis according to 2017 eular acr classification criteria clinical trials.

Also recruiting in Europe

Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Multicenter, Parallel-group, Double-blind, 2-Arm, Phase III Study to Investigate the Efficacy and Safety of Anifrolumab Administered as Subcutaneous Injection and Added to Standard of Care Compared with Placebo Added to Standard of Care in Adult Participants with Idiopathic Inflammatory Myopathies (Polymyositis and Dermatomyositis)

Denmark, Belgium, Italy, Sweden, Netherlands, Spain +7 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria trials by city

Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Toronto Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Vancouver Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Montreal Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Calgary Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Edmonton Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Ottawa Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Winnipeg Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Quebec City Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Hamilton Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Kitchener Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in London Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Halifax Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in New York Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Los Angeles Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Chicago Polymyositis Or Dermatomyositis According To 2017 Eular Acr Classification Criteria in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease